Commercialization

Hackensack Meridian Health Research Institute Creates First Spin-off Company, EValuate Diagnostics

Retrieved on: 
Wednesday, October 4, 2023
Hackensack Meridian Health, CDI, Commercialization, Evaluation, Neoplasm, Infection, Cancer, Hackensack Meridian School of Medicine, Breast, Medicine, Research, Biomarker, RNA, Lung, Science, EVS, Bear, Discovery, Seminal vesicles, Prostate Cancer Foundation, Patient, Physician, Blood, FACS, Den, Exosome, Health, Laboratory, Disease, Medical imaging, Pharmaceutical industry, Innovation, Urology

EDISON, N.J., Oct. 4, 2023 /PRNewswire/ -- The Hackensack Meridian Health Research Institute and its Office of Innovation and Commercialization have taken the step of establishing the first spin-off company based on science developed within the Hackensack Meridian Health network. The company aims to make tests detecting cancer and other diseases earlier than ever before.

Key Points: 
  • "This is a remarkable breakthrough for our health network, and for patients of the future," said Robert C. Garrett, FACHE, chief executive officer of Hackensack Meridian Health.
  • "We are taking the science produced by our terrific minds at the Hackensack Meridian Health Research Institute, and then moving it to the market so it can benefit all.
  • "This is a new milestone for innovation at Hackensack Meridian Health," said Ihor Sawczuk, M.D., FACS, Hackensack Meridian Health's president of Academics, Research and Innovation, founding chair of the Hackensack Meridian Health Research Institute, and also associate dean of Clinical Integration and professor and chair emeritus of Urology at the Hackensack Meridian School of Medicine.
  • The Office of Innovation and Commercialization launched in 2022 and promises to support innovations and discoveries across Hackensack Meridian Health.

MHI Introduces New Container-Type Data Center with Immersion/Air-Cooled Hybrid Cooling System

Retrieved on: 
Wednesday, October 4, 2023
KDDI, Commercialization, Culture, Kilowatt-hour, PUE, MHI, Water, Immersion, Environment, NEC, YHH, Transformer, Information technology, Renewable energy

- Commercialization planned by the end of FY2023 utilizing technologies related to micro-edge data centers and server cooling.

Key Points: 
  • - Commercialization planned by the end of FY2023 utilizing technologies related to micro-edge data centers and server cooling.
  • TOKYO, Oct 4, 2023 - (JCN Newswire) - Mitsubishi Heavy Industries, Ltd. (MHI) has developed a new 40kVA-class 12ft container-type data center with an immersion/air-cooled hybrid cooling system capable of simultaneously housing servers utilizing three types of cooling methods: immersion cooling (25kVA), air cooling (8kVA), and water cooling (8kVA).
  • The newly developed data center is the successor to the container-type immersion cooling data center(1) that has been under development since 2021.
  • Going forward, MHI Group will apply various cooling technologies and zero emission power products at data centers that utilize high-performance servers.

PyroGenesis Provides Update on the PUREVAP™ Quartz Reduction Reactor and Fumed Silica Projects with HPQ Silicon Inc.

Retrieved on: 
Tuesday, October 3, 2023
Quartz, Steps, Partnership, Commercialization, HPQ, Pollution, QRR, GHG, Carbon, Silica gel, FRA, Projection, Silicon dioxide, Silicon, Plasma, 0 A.D. (video game), US, FSR, TSX, Path, Greenhouse, News, CO2, Fused quartz, Fine chemical, Iron ore, Cement

As part of the terms of both projects with HPQ, PyroGenesis benefits from a royalty payment representing 10% of the Client’s eventual sales, with set minimums.

Key Points: 
  • As part of the terms of both projects with HPQ, PyroGenesis benefits from a royalty payment representing 10% of the Client’s eventual sales, with set minimums.
  • With respect to the FSR with HPQ Silica Polvere Inc. (“HPQ Polvere”), a wholly owned subsidiary of HPQ, this royalty stream, can, at any time, be converted by PyroGenesis into a 50% ownership in HPQ Polvere.
  • As noted by HPQ , the demand for silicon (Si) is projected to surpass 3.8 million tonnes and be valued between US$15 billion and US$20 billion by 2025.
  • Next Steps for Fumed Silica Reactor: The Path to Commercialization
    “In the FSR project, PyroGenesis is the unique supplier of a technology capable of using quartz (SiO2) as a raw material to produce commercial-grade fumed silica, in a single step.

BranchOut Food Inc. Announces Participation in the LD Micro Main Event XVI

Retrieved on: 
Friday, September 29, 2023
Operation, Commercialization, Friends, Dehydration, Sweet Sixteen, Main, IP, BOF, BranchOut

Presentation on Wednesday, October 4th at 2:00 PM PT

Key Points: 
  • "We know what this event means to our industry and how much people enjoy attending.
  • I am honored to host our close friends and allies for our "Sweet Sixteen" installment of the Main Event," stated Chris Lahiji, Founder of LD Micro.
  • Presentation to cover: BranchOut Founding Story, BranchOut technology, IP, and market advantages, Commercialization traction and sales pipeline, Go to market strategy, Operations/manufacturing in Peru and Chile.
  • The 2023 LD Micro Main Event XVI will run from October 3rd to the 5th at the Luxe Sunset Boulevard Hotel in Los Angeles.

Coave Therapeutics to Present at Upcoming Conferences

Retrieved on: 
Thursday, September 28, 2023
Medicine, GBA1, Commercialization, PDE6B, Safety, Efficacy, PDT, Retinitis pigmentosa, ID, CNS, Central nervous system, Science, Eye, CEST, Regulation, Pharmaceutical industry, Patient

Paris, France, September 28, 2023 – Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies for CNS (Central Nervous System) and eye diseases, announces that CEO Rodolphe Clerval will be presenting to investors and peers at the following Investor and Industry conferences:

Key Points: 
  • Paris, France, September 28, 2023 – Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies for CNS (Central Nervous System) and eye diseases, announces that CEO Rodolphe Clerval will be presenting to investors and peers at the following Investor and Industry conferences:
    Presenting on October 10 at 13:15 PDT and on panel “Science Slam: Path To Commercialization In Gene Therapy” at 14:00 PDT
    In addition, science and data from Coave’s pipeline programs will be presented at the following Scientific, Medical & Regulatory Conferences:
    Oral presentation by Professor G. Le Meur: “Design of a Phase 1/ 2 Trial to Study the Safety and Efficacy of a Unilateral Subretinal Administration of HORA-PDE6B in Patients with Retinitis Pigmentosa (RP) Harbouring Mutations in the PDE6B (Phosphodiesterase 6B) Gene Leading to a Defect in PDE6B Expression.”
    Oral Presentation by Dr. M.A.
  • Burlot: “Intrastriatal injection of S0112AAV2-GBA1 is an efficient strategy to treat patients suffering from Parkinson’s disease related to GBA1 mutations.” Presentation on 27 October, 08:30-10:00 CEST (ID# OR65)

Ensovi Leverages Ginkgo Enzyme Services to Optimize Cell-Free Carbon Fixation Process for Biomanufacturing

Retrieved on: 
Thursday, September 28, 2023
DNA, Partnership, Commercialization, Senior, Carbon dioxide, Enzyme, Recycling, Synthetic biology, NYSE, Chemical industry, Ginkgo Bioworks, Ginkgo, Engineering, Acetyl-CoA, Organic, CO2, Fine chemical

Under the terms of the agreement, Ginkgo will support the discovery and development of enzymes needed to bring Ensovi's cell-free biomanufacturing platform to market.

Key Points: 
  • Under the terms of the agreement, Ginkgo will support the discovery and development of enzymes needed to bring Ensovi's cell-free biomanufacturing platform to market.
  • Ginkgo Enzyme Services offers partners end-to-end support for the discovery, engineering, optimization, and scale-up of enzymes for diverse applications.
  • Through the partnership, Ginkgo will leverage its suite of services, including metagenomic enzyme discovery, as well as enzyme optimization for function and stability to support Ensovi's applications.
  • To learn more about Ginkgo Enzyme Services, please visit ginkgobioworks.com/enzyme-services/ .

ARPA-H Selects Pegasus Park in Dallas as a HUB Location for its Newly Established Federal Agency

Retrieved on: 
Wednesday, September 27, 2023
Transfer, Commercialization, DARPA, Impact, Sutro Biopharma, Innovation, ARPA, Advanced Research Projects Agency for Health, Cell, Ecosystem, Summit, Space

DALLAS, Sept. 26, 2023 /PRNewswire/ -- The 9th Annual BioNTX iC³ Life Science Summit is just two days away, and today's announcement from the newly established federal agency, the Advanced Research Projects Agency for Health (ARPA-H), marks the beginning of an exciting week for the bioscience community. The two-day event, taking place on September 28, 2023, and Friday, September 29, 2023, will bring together bioscience and healthcare innovation leaders, adding celebration to the event following this significant ARPA-H announcement.

Key Points: 
  • The Dallas ARPA-H Hub will be strategically located at Pegasus Park, working in close collaboration with counterparts in Austin, Houston, and San Antonio.
  • Its primary focus will be on enhancing customer experience, conducting user testing, promoting adoption, ensuring access, and building trust in ARPA-H projects.
  • Kathleen Otto, CEO of BioNTX, expressed her enthusiasm, stating, "What an exciting week for the bioscience community in North Texas.
  • We have firsthand experience of why Pegasus Park is the ideal location for an ARPA-H Hub, given that BioNTX offices are on the same campus.

MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights

Retrieved on: 
Tuesday, September 26, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Workforce, Bevacizumab, Commercialization, Doctor of Philosophy, Lymphoid leukemia, Food, Medicines and Healthcare products Regulatory Agency, Calendar, Clinical trial, Cancer, OXPHOS, Aplastic anemia, Medication, Pharmaceuticals and Medical Devices Agency, Acute myeloid leukemia, PI3K, Kyowa Kirin, Development, VEGF, AML, BCL2, Glycolysis, Patient, Investment, PMDA, Colorectal cancer, Neoplasm, MEI, Research, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, CDK9, Venetoclax, Safety, Pharmaceutical industry, Cryptocurrency, Shareholder

MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year ended June 30, 2023.

Key Points: 
  • MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year ended June 30, 2023.
  • The certified results showed that 59.70% of outstanding shares were voted, of which 47.86% voted in favor of the proposed transaction, and 51.44% against.
  • In May 2023, MEI regained compliance with the Nasdaq minimum bid requirement after the Company implemented a 1-for-20 reverse stock split in April 2023.
  • As of June 30, 2023, MEI had $100.7 million in cash, cash equivalents, and short-term investments with no outstanding debt.

Strata Oncology Announces Appointment of Goz Alhir as Senior Vice President of Commercialization

Retrieved on: 
Tuesday, September 26, 2023
Commercialization, Therapy, Senior, Health, ANN, Stratum, Cancer, Lilly, Patient, Medicine, NanoString Technologies, Knowledge, Growth, Science, Nursing

ANN ARBOR, Mich., Sept. 26, 2023 /PRNewswire/ -- Strata Oncology, Inc. ("Strata"), a next-generation precision oncology company enabling smarter cancer treatment, today announced the appointment of Goz Alhir as Senior Vice President, Commercialization. With more than 25 years of healthcare leadership experience, Alhir brings a wealth of knowledge to the role and is eager to join the company in bringing its transformative treatment selection testing to the market.

Key Points: 
  • ANN ARBOR, Mich., Sept. 26, 2023 /PRNewswire/ -- Strata Oncology, Inc. ("Strata"), a next-generation precision oncology company enabling smarter cancer treatment, today announced the appointment of Goz Alhir as Senior Vice President, Commercialization.
  • "It is an honor to join Strata Oncology at such an important time in the company's growth," said Goz Alhir, Senior Vice President, Commercialization, at Strata Oncology.
  • Alhir is a top-performing executive with extensive experience across the oncology healthcare ecosystem, from oncology diagnostics and therapeutics to precision medicine and biopharma.
  • "Strata Oncology is thrilled to welcome Goz to our executive leadership team," said Dan Rhodes, Ph.D., co-founder and CEO of Strata Oncology.

Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer

Retrieved on: 
Monday, September 25, 2023
Tufts University, Commercialization, Biogen, Business, Lead, Babson College, Multiple sclerosis, MS, Business administration, Patient, Sickle cell disease, Biology, Master of Business Administration, Therapy, Pan-Mass Challenge, Management, Pharmaceutical industry, EU, Editas Medicine

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Caren Deardorf as the Company’s first Chief Commercial and Strategy Officer.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Caren Deardorf as the Company’s first Chief Commercial and Strategy Officer.
  • “As we drive our lead program EDIT-301 towards commercialization, I am happy to welcome a commercial leader of Caren’s caliber to Editas.
  • Caren has a proven ability to translate early discovery and clinical assets into robust business strategy with disciplined portfolio prioritization and value creation.
  • Caren’s expertise and track record make her the ideal leader to help Editas reach this goal for patients,” said Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer, Editas Medicine.